ANN ARBOR – Genetics Squared has appointed Dr. Peter Lenehan as chief medical officer and Dr. David Fry chief science officer, former targeted oncology drug development team members at Pfizer and Parke-Davis/Warner-Lambert.
“Genetics Squared is very excited to add these two exceptional individuals to its management team,” said president and CEO John Freshley. “They have successfully worked together in the past and that is an important additional benefit to the company.”
As chief medical officer, Dr. Lenehan will be responsible for the acquisition and clinical development of “promising but struggling” clinical oncology compounds using Genetics Squared’s evolutionary drug development technology. Most recently, Dr. Lenehan was director of clinical oncology at Pfizer, where he led the early clinical development of many cancer therapies for solid tumors.
Dr. Fry is already an active member of Genetics Squared’s Scientific Advisory Board. As chief science officer, Dr. Fry will lead the discovery of appropriate biomarkers and combinations of biomarkers to identify the optimal patient population for drugs in-licensed by the company for redevelopment.
